Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

Trial Profile

An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Dec 2018

At a glance

  • Drugs Pitolisant (Primary)
  • Indications Narcolepsy
  • Focus Expanded access; Therapeutic Use
  • Acronyms PEACE
  • Sponsors Harmony Biosciences
  • Most Recent Events

    • 05 Sep 2018 According to a Harmony Biosciences media release, data from this expanded access program including the design and methodology of the program, as well as initial data, including patient demographics, baseline characteristics and safety and tolerability results will be presented at the upcoming 7th International Symposium on Narcolepsy in Beverly, MA (Sep 9 to 13; 2018).
    • 06 Apr 2018 Status changed from suspended to recruiting.
    • 15 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top